CompletedNot Applicable

Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment

United States32 participantsStarted 2016-09-19

Plain-language summary

People with post-stroke aphasia are left with some degree of chronic deficit for which current rehabilitative treatments are variably effective. This study investigates the behavioral and neural effects of multiple consecutive cerebellar tDCS sessions coupled with computerized naming therapy in stroke survivors with aphasia.

Who can participate

Age range

18 Years – 100 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants must have sustained a left hemisphere stroke. * Participants must be fluent speakers of English by self-report. * Participants must be capable of giving informed consent or indicating another to provide informed consent. * Participants must be age 18 or older. * Participants must be premorbidly right handed. * Participants must be at least 6 months post stroke. * Participants must have an aphasia diagnosis as confirmed by the Boston Diagnostic Aphasia Examination (BDAE) Short Form. * Participants must achieve at least 65% accuracy on screening task (comparable to treatment task) on 1 of 3 attempts Exclusion Criteria: * Participants with lesion involving the right cerebellum * Previous neurological or psychiatric disease. * Seizures during the previous 12 months. * Uncorrected visual loss or hearing loss by self-report. * Use of medications that lower the seizure threshold (e.g., methylphenidate, amphetamine salts). * Use of N-methyl-D-aspartate receptor (NMDA) antagonists (e.g., memantine). * \> 80% (140 out of 175) correct responses on the Philadelphia Naming Test at baseline. * History of brain surgery or any metal in the head. * Scalp sensitivity (per participant report).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Accuracy of Naming Untrained Pictures (Philadelphia Naming Test:PNT) Pre-treatment to Post-treatment

Timeframe: Before and after 15 sessions (3-5 sessions per week; up to 5 weeks) of treatment.

Trial details

NCT IDNCT02901574

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-20

Results submitted2023-02-23

View on ClinicalTrials.gov More Stroke trials